Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Prevention02:59

Cancer Prevention

8.6K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
8.6K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

7.3K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.3K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.5K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.5K
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

6.6K
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
6.6K
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

2.1K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.1K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

60
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of FUT2 rs601338 Genotype with Colonic Mucosal Microbiome Composition, Post-Transplant Bacteremia, and All-Cause Mortality After Liver Transplantation for Primary Sclerosing Cholangitis: A Retrospective Cohort Study.

Journal of clinical medicine·2026
Same author

Genome-wide association and Mendelian randomization analyses link <i>Helicobacter pylori</i> infection to Human Leukocyte Antigen polymorphisms and autoimmune diseases.

medRxiv : the preprint server for health sciences·2026
Same author

Re-evaluation of Helicobacter pylori diagnostic methods: A multicenter clinical diagnostic accuracy study.

The Journal of infection·2026
Same author

Expression of low molecular weight protein tyrosine phosphatase in gastric cancer and its association with clinical outcomes and oncogenic hallmarks.

Molecular medicine (Cambridge, Mass.)·2026
Same author

Osteocyte transition induced by quiescent vascular smooth muscle cells through paracrine signaling is independent of shear stress.

Biochimica et biophysica acta. Molecular cell research·2025
Same author

Intestinal barrier alterations in mice following fecal microbiota transplant from children of IBD-affected mothers.

Med (New York, N.Y.)·2025

Related Experiment Video

Updated: Mar 10, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NF&#954;B Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.7K

Fumarates and Cancer.

Gwenny M Fuhler1, Hester Eppinga1, Maikel P Peppelenbosch1

  • 1Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.

Trends in Molecular Medicine
|December 18, 2016
PubMed
Summary

Tumor cells accumulating tricarboxylic acid (TCA) cycle metabolites like fumarate can drive cancer progression and metastasis. Fumarate specifically alters epigenetic regulation of the miR-200bc/429 cluster, promoting tumor aggressiveness in renal cancers.

Keywords:
cancerepithelial-to-mesenchymal transitionfumaratemetastasis

More Related Videos

A Protocol for Detecting and Scavenging Gas-phase Free Radicals in Mainstream Cigarette Smoke
09:23

A Protocol for Detecting and Scavenging Gas-phase Free Radicals in Mainstream Cigarette Smoke

Published on: January 2, 2012

19.9K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K

Related Experiment Videos

Last Updated: Mar 10, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NF&#954;B Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.7K
A Protocol for Detecting and Scavenging Gas-phase Free Radicals in Mainstream Cigarette Smoke
09:23

A Protocol for Detecting and Scavenging Gas-phase Free Radicals in Mainstream Cigarette Smoke

Published on: January 2, 2012

19.9K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K

Area of Science:

  • Biochemistry
  • Oncology
  • Epigenetics

Background:

  • Accumulation of tricarboxylic acid (TCA) cycle intermediates in tumors can promote epithelial-to-mesenchymal transition (EMT).
  • The precise molecular mechanisms linking TCA metabolites to EMT and tumor aggressiveness are not fully understood.
  • Fumarate hydratase-deficient renal cancers exhibit accumulation of the oncometabolite fumarate.

Purpose of the Study:

  • To investigate the role of accumulated fumarate in driving tumor aggressiveness.
  • To elucidate the epigenetic mechanisms by which fumarate influences cancer progression.
  • To explore the potential clinical implications of fumarate accumulation in cancer.

Main Methods:

  • Analysis of fumarate accumulation in renal cancer cells.
  • Assessment of epigenetic modifications in cancer cells.
  • Evaluation of the impact on the miR-200bc/429 microRNA cluster.
  • Correlation of fumarate levels with tumor aggressiveness markers.

Main Results:

  • Fumarate accumulation in tumor cells was linked to increased aggressiveness.
  • Fumarate was found to induce epigenetic changes within the cancer cells.
  • These epigenetic alterations specifically affected the antimetastatic miRNA cluster, miR-200bc/429.
  • This mechanism contributes to the aggressive phenotype observed in fumarate-accumulating cancers.

Conclusions:

  • Accumulated fumarate acts as an oncometabolite, promoting tumor aggressiveness through epigenetic reprogramming.
  • Epigenetic modification of the miR-200bc/429 cluster by fumarate is a key mechanism driving cancer progression.
  • Targeting fumarate accumulation or its downstream effects may offer therapeutic strategies for renal cancer.